Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: keokalani'nui who wrote (1679)	9/17/2000 7:03:33 PM
From: greedsgd_2000	Read Replies (1) \| Respond to of 52153

Lots of undervaluation with these cancer vaccine biotechs - probably 5 or 10 with major programs underway, including CEGE and AVii - both real cheap from a valuation standpoint. Interesting thing is few have tested with large populations of nonrefractive patients - due to the ethical considerations and so forth. However, it will be interesting when they eventually go into trials with both early stage but also ultra-early stage patients. The results may look better. CEGE just published early clinical human trials with a patient specific type approach -and the results were not that bad. CEGE I believe is enrolling for the followup Phase 1/2 vaccine programs which will include larger groups of nonrefractive patients (partly in Japan I believe) These "disruptions" via ultra early noninvasive diagnostics about to occur, should shift the whole treatment approach forward in many respects.